Goldman Sachs Group Inc. Buys 283,596 Shares of IQVIA Holdings Inc. $IQV

Goldman Sachs Group Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 21.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,592,554 shares of the medical research company’s stock after purchasing an additional 283,596 shares during the quarter. Goldman Sachs Group Inc.’s holdings in IQVIA were worth $358,978,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Bridges Investment Management Inc. grew its stake in IQVIA by 1.1% in the fourth quarter. Bridges Investment Management Inc. now owns 9,288 shares of the medical research company’s stock valued at $2,094,000 after purchasing an additional 103 shares in the last quarter. Fiduciary Family Office LLC grew its stake in IQVIA by 30.7% in the fourth quarter. Fiduciary Family Office LLC now owns 8,043 shares of the medical research company’s stock valued at $1,813,000 after purchasing an additional 1,890 shares in the last quarter. Dynasty Wealth Management LLC bought a new position in IQVIA in the fourth quarter valued at approximately $377,000. Meridian Management Co. boosted its stake in shares of IQVIA by 1.1% during the 4th quarter. Meridian Management Co. now owns 29,288 shares of the medical research company’s stock worth $6,602,000 after acquiring an additional 309 shares during the period. Finally, Natixis Advisors LLC boosted its stake in shares of IQVIA by 46.8% during the 4th quarter. Natixis Advisors LLC now owns 76,065 shares of the medical research company’s stock worth $17,146,000 after acquiring an additional 24,236 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of IQV opened at $183.56 on Friday. The business has a 50-day simple moving average of $172.12 and a two-hundred day simple moving average of $194.94. IQVIA Holdings Inc. has a 12-month low of $147.62 and a 12-month high of $247.04. The stock has a market cap of $30.64 billion, a PE ratio of 22.75, a PEG ratio of 1.60 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the company posted $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. UBS Group dropped their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a report on Friday, March 6th. HSBC set a $210.00 price target on IQVIA in a report on Wednesday. Finally, BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.